ReviewFrontiers in pharmacology2025
Advancements in nasal drug delivery system of natural products.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antidepressant effects and therapeutic potential of naringenin: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- P2 Receptors as Therapeutic Targets in Allergic Rhinitis: Insights From the Use of Natural Products and Preclinical Studies.Journal of immunology research · 2026Review
- Anthocyanins Modulation of Gut Microbiota to Reverse Obesity-Driven Inflammation and Insulin Resistance.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasal drug delivery offers a non-invasive route with rapid absorption and the ability to bypass first-pass metabolism, making it promising for central nervous system (CNS) disorders, nasal diseases such as allergic rhinitis, and other chronic conditions by enabling targeted delivery and crossing the blood-brain barrier. Purpose: To review the advantages of nasal delivery, therapeutic potential of natural products, and how drug delivery systems may overcome bioavailability and solubility issues. Study Design: A literature review analyzing mechanisms, clinical applications, and limitations of natural products in nasal delivery. Methods: Relevant articles published before January 2025 were retrieved from Google Scholar, PubMed, ScienceDirect, Scopus, Web of Science, Springer, and official sources. Results: Nasal administration improves the bioavailability and absorption of natural products, enhancing anti-inflammatory, antioxidant, neuroprotective, and anti-allergic effects. However, poor solubility and stability remain barriers, which may be mitigated by nanocarriers, liposomes, and other advanced systems. Conclusion: Combining nasal drug delivery with natural products is a promising strategy for treating CNS, nasal, and chronic diseases, potentially improving clinical efficacy and expanding therapeutic options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.